Erythropoietin (EPO) for Anemia of Prematurity: Indian Dosing Protocol

Introduction to Anemia of Prematurity

Anemia of prematurity (AOP) is a normocytic, normochromic anemia that affects virtually all preterm neonates, particularly those born before 32 weeks of gestation. It results from a combination of physiological factors including inadequate erythropoietin production due to immature renal oxygen-sensing mechanisms, shortened red blood cell lifespan (60 to 90 days versus 120 days in adults), rapid somatic growth outpacing erythropoiesis, and iatrogenic blood losses from frequent laboratory sampling. In Indian NICUs, iatrogenic phlebotomy loss is a major contributor, with preterm infants undergoing 15 to 25 blood draws during the first two weeks of NICU admission.

Management of AOP involves a multimodal approach: minimizing phlebotomy losses, implementing restrictive transfusion triggers, optimizing nutritional support, and in selected cases, using recombinant human erythropoietin (rHuEPO) to stimulate endogenous red cell production. This article reviews the evidence base, dosing protocols, and practical implementation of EPO therapy for anemia of prematurity in the Indian NICU context, addressing both government and private hospital settings.

Pathophysiology of Anemia of Prematurity

Contributing Factors

• Inadequate EPO production: Fetal erythropoietin is produced predominantly by the liver, which has a higher oxygen threshold for EPO secretion than the adult kidney. The transition from hepatic to renal EPO production occurs during the third trimester. Preterm infants have inappropriately low EPO levels for their degree of anemia because this transition is incomplete at birth.
• Shortened RBC lifespan: Neonatal red blood cells containing fetal hemoglobin have a lifespan of 60 to 90 days, accelerating the decline in hemoglobin levels postnatally.
• Rapid growth: VLBW infants may double their birth weight within 6 to 8 weeks, expanding blood volume faster than erythropoiesis can maintain adequate hemoglobin levels.
• Iatrogenic losses: Cumulative blood sampling may account for 10 to 40 percent of total blood volume in VLBW infants during the first weeks, making it the most modifiable risk factor for AOP.

Natural History

Hemoglobin levels in preterm neonates typically reach their nadir at 4 to 8 weeks of postnatal age. In extremely preterm infants below 28 weeks, the nadir hemoglobin may fall to 7 to 8 g/dL, compared to 9 to 11 g/dL in term infants at their physiological nadir. Without intervention, more preterm infants experience earlier and deeper hemoglobin nadirs.

Pharmacology of Recombinant Human Erythropoietin

Mechanism of Action

Erythropoietin binds to EPO receptors on erythroid progenitor cells in the bone marrow, activating the JAK2-STAT5 signaling pathway to stimulate proliferation, differentiation, and maturation of erythroid precursors into reticulocytes and mature red blood cells. EPO also inhibits apoptosis of late erythroid progenitors. Beyond its erythropoietic effect, EPO has neuroprotective, anti-inflammatory, and angiogenic properties mediated through EPO receptors expressed in non-hematopoietic tissues including the brain and retina.

Pharmacokinetics in Neonates

Parameter	Preterm Neonate	Term Neonate
Half-life (IV)	6-8 hours	4-6 hours
Half-life (SC)	12-18 hours	10-14 hours
Bioavailability (SC)	40-50%	40-50%
Volume of distribution	50-70 mL/kg	40-60 mL/kg
Clearance	Higher per kg than adults	Higher per kg than adults

Neonates have higher weight-adjusted EPO clearance than adults, necessitating relatively higher doses per kilogram and more frequent administration. The subcutaneous route provides sustained absorption and is preferred over IV in most protocols.

Dosing Protocol for Indian NICUs

Patient Selection

EPO therapy should be considered for VLBW neonates (birth weight below 1500 grams) and/or gestational age below 32 weeks who are clinically stable and at high risk of requiring multiple red blood cell transfusions. Initiation is recommended once the infant is tolerating sufficient enteral feeds to support iron supplementation, typically at 1 to 4 weeks of postnatal age.

Dosing Regimens

Protocol	Dose	Route	Frequency	Duration
NNF recommended	250-400 IU/kg	Subcutaneous	3 times/week	4-6 weeks
Alternative daily	100-200 IU/kg	Subcutaneous	5 times/week	4-6 weeks
High-dose protocol	400-500 IU/kg	Subcutaneous	3 times/week	6-8 weeks

Essential Co-Supplementation

• Elemental iron: 6 mg/kg/day divided into 2 to 3 oral doses. This is substantially higher than standard preterm iron supplementation (2 to 3 mg/kg/day) because EPO therapy dramatically increases iron utilization. Without adequate iron, EPO-stimulated erythropoiesis fails due to functional iron deficiency.
• Folic acid: 50 mcg daily to support DNA synthesis in rapidly dividing erythroid progenitors.
• Vitamin E: 15 to 25 IU/day to protect new red blood cell membranes from oxidative damage.
• Adequate protein: Ensure protein intake of 3.5 to 4 g/kg/day to provide amino acid substrate for hemoglobin synthesis.

Monitoring During EPO Therapy

• Hemoglobin and reticulocyte count: Weekly. A reticulocyte count rising above 4 to 6 percent within 1 to 2 weeks indicates an adequate erythropoietic response.
• Serum ferritin: Every 2 weeks. Target above 100 mcg/L. Ferritin below 50 mcg/L despite oral iron supplementation may warrant IV iron supplementation or EPO dose reduction.
• Complete blood count: Weekly to monitor all cell lines. Platelet counts may increase mildly with EPO therapy.
• ROP screening: Standard gestational-age-based ROP screening continues throughout EPO therapy.

Evidence Base: Key Trials

Early vs Late EPO: Cochrane Reviews

The Cochrane reviews on early EPO (started before 8 days) and late EPO (started between 8 and 28 days) provide the strongest evidence for clinical decision-making. Early EPO reduces the number of RBC transfusions per infant by approximately 0.22 but does not significantly reduce donor exposure. Late EPO reduces both the number of transfusions (by approximately 0.64 per infant) and the proportion of infants requiring any transfusion, representing a more meaningful clinical benefit.

The PENUT Trial

The Preterm Erythropoietin Neuroprotection Trial (2020) randomized 741 extremely preterm infants to high-dose EPO or placebo. The primary neuroprotection hypothesis was not confirmed, with no significant difference in death or severe neurodevelopmental impairment at 2 years. However, the EPO group required fewer transfusions. Importantly, there was no significant increase in adverse events including severe ROP, NEC, or death, providing reassurance about EPO safety even at high doses in extremely preterm infants.

Cost-Effectiveness in Indian NICUs

Recombinant EPO is available from multiple Indian pharmaceutical manufacturers at INR 200 to 800 per 2000 IU vial. A typical 4-week course for a 1.2 kg infant using 300 IU/kg three times weekly requires approximately 4000 IU per week, costing INR 400 to 1600 per week. This must be weighed against the cost of packed RBC transfusion (INR 500 to 1500 per unit, including cross-matching and administration), the infectious risks of transfusion, and the immunological consequences of donor exposure. In Indian NICUs with high phlebotomy rates and limited access to leukoreduced blood products, EPO therapy may offer additional value beyond transfusion reduction.

Strategies Beyond EPO for Reducing Transfusions

EPO therapy should be considered as one component of a comprehensive anemia prevention strategy in Indian NICUs.

• Delayed cord clamping: Delaying cord clamping by 30 to 60 seconds increases neonatal blood volume by approximately 10 to 15 mL/kg, significantly reducing early transfusion needs.
• Minimizing phlebotomy losses: Use micro-sampling techniques, point-of-care testing requiring small volumes, non-invasive monitoring where possible, and HEAMAC micro-volume blood gas analysers to reduce cumulative blood loss.
• Restrictive transfusion triggers: The ETTNO trial demonstrated that restrictive transfusion thresholds are non-inferior to liberal thresholds for neurodevelopmental outcomes, supporting evidence-based transfusion practices.
• Iron supplementation: Early initiation of enteral iron (2 to 3 mg/kg/day from 2 weeks, increasing to 6 mg/kg/day with EPO therapy) ensures adequate substrate for erythropoiesis.

Adverse Effects of EPO

• Injection site reactions: Erythema and mild swelling at subcutaneous sites. Rotate between thighs, abdomen, and upper arms.
• Neutropenia: Transient mild reduction in neutrophil count reported in some studies. Monitor weekly CBC.
• Hypertension: Rare at standard neonatal doses but reported in adult EPO therapy.
• ROP: EPO receptors are present in retinal tissue. While clinical trials have not confirmed increased severe ROP risk, ongoing vigilance is warranted.

Conclusion

Erythropoietin therapy provides a pharmacological approach to stimulating erythropoiesis and reducing transfusion requirements in preterm neonates with anemia of prematurity. While the benefit is modest, it forms a valuable component of a comprehensive anemia management strategy that includes delayed cord clamping, minimized phlebotomy, restrictive transfusion thresholds, and optimized nutrition. In Indian NICUs, where blood product safety and availability may be variable, EPO therapy offers an additional tool for reducing transfusion exposure in the most vulnerable preterm population.